Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.

Publikation

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.

Wissenschaftlicher Artikel/Review - 22.11.2023

Schuler Alexandra, Huser J, Schmid Sebastian M, Schär Sämi, Scherz Amina, Gautschi Oliver Pascal, Mauti Laetitia A, von Briel Thomas, Waibel Christine, Wannesson Luciano, Pankovics J, Mark Michael Thomas, Rothschild Sacha I, Addeo Alfredo, Janthur W, Siano Marco, Boos L, Britschgi Christian, Früh Martin

Zitation

Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark M, Rothschild S, Addeo A, Janthur W, Siano M, Boos L, Britschgi C, Früh M. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung Cancer 2023; 187:107427.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lung Cancer 2023; 187

Veröffentlichungsdatum

22.11.2023

eISSN (Online)

1872-8332

Seiten

107427

Kurzbeschreibung/Zielsetzung

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for patients with EGFR mutated non-small cell lung cancer as first-line treatment. However, treatment resistance inevitably emerges and may present as oligo-progressive disease (OPD) or systemic progressive disease (SPD). The incidence of OPD on first-line osimertinib is unknown.